GlassScriptPhysician profile
Mukunda Singh
NPI 1487185534
$981.21
in general payments reported to CMS, 2019-2025
10 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $72.91 · 2024: $754 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $248.54 | 2023-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $181.79 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $138.22 | 2024-2025 | |
| Insulet Corporation | $129.31 | 2024-2025 | Omnipod |
| Glaxosmithkline, LLC. | $91.45 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.93 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $40.78 | 2024-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $39.51 | 2024-2025 | |
| Dynavax Technologies Corporation | $18.66 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $17.02 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukunda Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.